🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

No DEA rescheduling of Schedule I psychedelics (psilocybin/MDMA) through 2026.

Predicted 2026-07-14 · Resolves 2026-12-31 · regulatory · USA
80%
ORACLE CONFIDENCE
⏳ Pending
Every outcome is scored publicly in the ledger.

Both psilocybin (the active compound in magic mushrooms) and MDMA (also known as ecstasy or molly) are currently in Schedule I — the US government's most restricted drug category, reserved for substances with no accepted medical use. Moving a drug out of Schedule I requires a formal scientific recommendation from a government health agency, followed by a lengthy public rulemaking process. Neither of those steps has started, so nothing will change before 2027.

Resolution rule: YES if, as of 2026-12-31, psilocybin and MDMA both remain listed in Schedule I per the DEA Controlled Substances list (dea.gov/drug-information/csa-schedules) with no final rescheduling rule published on federalregister.gov. NO if either substance is moved out of Schedule I. Checked 2026-12-31.

Scheduling requires an HHS scientific recommendation followed by DEA notice-and-comment rulemaking; no such HHS recommendation has been transmitted. Appropriations activity does not trigger rescheduling. DEA enforcement posture remains unchanged.

5 new falsifiable predictions, every day at 12:05 PM ET.
Get tomorrow's Oracle →